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A major challenge in post-genomic research is to understand how 
physiological and pathological phenotypes arise from the networks of 
expressed genes1 and to develop powerful tools for translating the 
information exchanged between gene and the organ system networks. 
Although different expression modules may contribute independently to 
different phenotypes2,3, it is difficult to interpret microarray experimental 
results at the level of single gene associations4. The global effects5 and 
response pathways6 of small molecules in cells have been investigated, but 
the quantitative details of the activation mechanisms of multiple pathways in 
vivo are not well understood. Similar response networks7,8,9 indicate similar 
modes of action10, and gene networks may appear to be similar despite 
differences in the behaviour of individual gene groups11,12. Here we establish 
the method for assessing global effect spectra of the complex signaling 
forms using Global Similarity Index (GSI) in cosines vector included angle. 
Our approach provides quantitative multidimensional measures of genes 
expression profile based on drug-dependent phenotypic alteration in vivo. 
These results make a starting point for identifying relationships between GSI 
at the molecular level and a step toward phenotypic outcomes at a system 
level to predict action of unknown compounds and any combination therapy. 
We applied both top-down and bottom-up approaches in this research 
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on the ischaemic mouse hippocampus (Fig.1). Baicalin (BA), jasminoidin 
(JA), cholic acid (CA), Concha margaritifera (CM) and nimodipine (NI) 13,14 
have different effects on neurons subjected to an ischaemic insult. IV after 
occlusion of the middle cerebral artery was significantly smaller after 
treatment with each compound except CM; the reduction in IV was greatest 
for NI (Fig.2a, F=17.01, *P < 0.05, **P < 0.01 vs. vehicle; mean ± SD, 
ANOVA, n = 7–9). In the vehicle- and sham-treated mice, 24.06% (90/374) 
of genes differed in their expression in the hippocampus. Although 90 genes 
exhibited highly significant differences in expression, only one-third (32 
genes) of the cDNAs showed average differences greater than twofold (Fig. 
2b). Compared with the vehicle-treated condition, expression differed in 99, 
72, 106, 62 and 62 genes in ischaemic mouse hippocampi treated with BA, 
JA, CA, CM, and NI, respectively. Only eight genes overlapped in the 
hippocampi treated with BA, JA, CA, and NI versus CM and vehicle, and 19 
genes were shared between all groups (Supp Table 1) (Fig. 2b). Based on 
data from a previous study15, these genes were expected to respond to 
ischaemic injury or are related to hippocampal function, except that 
Selenbp2 was null. An interesting contradiction is that the eight overlapping 
genes should contribute most to the pharmacological effect, but this was not 
supported by direct comparison in PCA (Fig.2c), which showed that PCA1 
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accounted for 56.3% and PCA1-2 for 67.8% of the pharmacological 
variation. This dominant pattern of expression of the top five major genes 
was clearly associated with G protein-coupled receptors (GPCRs) and Ras 
transcription, which did not overlap in the larger altered genes that protect 
against cerebral ischaemia such as RGS6, Cbx3, and Grb2 (Fig.2c)16. Only 
three overlapping genes in black pane (Fig.2d) contributed to the 
pharmacological effect based on the changed phenotypes, although 15 genes 
were shared in all compound groups (Suppl Table 2). The PCA showed that 
another five top genes might contribute to the pharmacological action, of 
which three genes Rgs6, Cbx3, and Grb2 in black pane were consistent with 
the above analysis (Fig.2c). PCA1 accounted for 60.29% and PCA2 14.50% 
of the variation. We infer that studying the effects of these candidate genes 
on pharmacological behaviour requires more than direct comparison analysis. 
Expressions of the eight selected genes observed by microarray analysis 
were independently confirmed by Real-time RT-PCR, which showed that 
Rgs6 had the highest activity (Fig.2e). 
We next designed two two-level factional experiments (Fig.3a-d) to 
study the mechanism of the concept of multivalent chemotherapy17. The 
ratios of overlapping genes (ROG) (23/133) and non-overlapping to 
overlapping genes (RNOG) (23/23/133) were 0.1729 and 4.78, respectively. 
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The ROG and RNOG of JA+BA versus BA or JA alone were 0.2667 
(44/165) and 2.75 (44/44/165), respectively (Fig.3c), suggesting the 
presence of more overlapping genes in the combination treatment (Fig.3b-d). 
Variations of gene expression profiles of eight pathways (Fig.3e) revealed 
that the extracellular signal-regulated kinase mitogen-activated protein 
kinase (Erk-MAPK) network shared different conditions in these treated 
groups because only some significantly altered genes emerged in this 
network (Fig.3f). One challenge that emerged was whether direct 
comparison analysis of the ROG and NROG could sufficiently reveal 
essential information about broad changes in so many pathways. 
Some differences in gene expression of less than 1.5-fold are robustly 
associated with behavioural differences3 and might be as important as those 
of genes with greater differences in expression condition. The fold change in 
expression may not be linearly related to phenotype behaviour because a 
smaller fold change (–1.72) had a higher correlation coefficient (0.95), and a 
larger fold change (–2.83) had a lower coefficient (0.85)18. We hypothesized 
that GSI could be used to quantitatively analyse the gene expression pattern 
of mouse hippocampus treated with BA, JA, CA, or NI alone or in 
combination. The GSI from this approach was greater than the Pearson 
coefficients, which were all < 0.7, and near to the Euclidean distance (the 
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range not wider than our approach) (Fig.4a). 
GSI after treatment with BA, JA, CA, or NI relative to the GSI of the 
sham treatment decreased gradually. The GSIs for BA and JA were similar 
(0.92) and were closer to that for the sham condition. Although the GSI for 
NI was 0.62 (Fig.4b), it produced significant IV. These results suggest that 
the same phenotype emerged despite the different profiles of gene 
expression; this observation reflects the chemical-dependent response and 
the integrated action of multi-target drugs.  
JA+CA shared different GSI with JA, CA and NI (0.57, 0.68, 0.93), 
respectively. So as to GSI exist in JA+BA with JA, BA and NI (0.81, 0.79, 
and 0.91) (Fig.4b). This suggests that GSI provides an approach independent 
of ROG and RNOG to represent the pattern of gene expression in 
chemogenomic profiling. The more overlapping genes in not represent 
higher GSI, so as to the lower overlapping ones. For example, we observed a 
higher percentage of overlapping genes (60%) do a lower GSI (0.72) for JA 
or NI, but a lower percentage of overlapping genes (44%) do a higher GSI 
(0.93) for JA+CA or NI (44%). 
 Although usually applied to relatively small numbers of genes19, 
hierarchical clustering in an independent analysis showed that JA+CA with 
NI, JA+BA with CA, and BA with JA, in three different categories (Fig.4c). 
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PCA1-3 accounted for 80% of the variation (Fig.4e), which was consistent 
with the clustering among the six groups (Fig.4d). Both methods validated 
the results of the GSI determined by varying the combination treatment. In 
independent experiments, the IV and neurological score was respectively 
significantly smaller (P = 0.028) in all groups except the CM group than in 
the vehicle group (Fig.5a,b). The CIV (Fig.5c) did not differ significantly 
between groups (F7,127 = 2.68, P > 0.05), but the PIV was smaller in all 
compound-treated groups (F7,127 = 20.71, P < 0.001). 
New morphological features appear predominantly because of 
modifications of the spatial patterns of gene expression20, confirming that 
similar phenotypes are secondary consequences of similar gene expression 
and that a transcription defect may be crucial to the development of a 
clinical syndrome. Although each drug profile represents the drug’s own 
signature at the transcriptional and molecular pharmacological levels21, most 
of the genes associated with a particular biological function are up- or 
down-regulated in a similar way, and the conserved functions of groups of 
genes should be reflected in similar patterns of gene expression in yeast, 
worms, fruit flies and humans22. GSI showed stable variations in multiple 
comparative studies and indicated a robust association between the GSI shift 
and plasticity of outcomes. Our results might provide new insights into the 
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mechanisms of a compound’s action in the ischaemic hippocampus that 
underlie pharmacological plasticity. We believe that systematic drug-design 
strategies should be directly against multiple targets, and that this novel 
drug-design paradigm might help develop more efficient compounds than 
the currently favoured single-target drugs12, which interactions of the most 
promising candidates23 appear to be fundamental to improving future stroke 
treatment. Integrating the clinical data from a patient’s records24 and other 
clinical or experimental variables25 is also promising. Thus, systems to 
augment expression analysis with automated literature extraction or 
organization26 are likely to prove valuable in drawing meaningful and 
reproducible conclusions. Our data demonstrated a molecular GSI of 
“pattern signature” in the mouse ischaemic hippocampus that was robustly 
associated with the pharmacological effects and provided quantitative 
assessment of a wide range of responses. These results support the idea that 
functional predictions based on molecular phenotype association27 provide a 
guide for studying combinations in system-oriented drug design9. 
Developing innovative scientific methods for discovery, validation, 
characterization and standardization of multi-component botanical 
therapeutics emerging synergic outcomes, and the network and pathways is 
essential28. 
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Figure 1. Overview of the systemic analysis line. a-c, Top-down approach. 
d-e, Bottom up method. StkE, Science Signal Transduction Knowledge 
Environment;MAPK, mitogen-activated protein kinase; PCA, principal 
component analysis;GSI, global similarity index; IV,Infarction volume; PIV, 
peripheral IV; CIV, central IV; IE,Indenpent experiment; RT-PCR, 
Reverse Transcription-Polymerase Chain Reaction. 
 
Figure 2 Plasticity of pharmacological phenotype and compound-dependent 
altered genes in the ischemic mouse hippocampus. a, Plasticity of IV in 
mouse hippocampus with sham, vehicle, BA, JA, CA, CM or NI treatment. 
*P < 0.05, **P < 0.01 vs. vehicle. b,Altered genes in the ischemic mouse 
hippocampus in animals treated with vehicle, CM, BA, JA, CA, or NI are 
indicated as a function of both the fold difference and statistical significance 
(P) for each of the 374 cDNAs on the microarray (tabulated P-values from 
ANOVA, n ≥ 9 animals per group). Statistical analysis was performed on the 
mean expression levels of all 374 cDNAs in each of six experimental groups. 
Numbers represent different (in italic) or overlapping genes in two or more 
groups. c, Different contributing genes in the direct comparison analysis and 
PCA. Eight overlapping genes existed in all pharmacologically significant 
groups compared with the vehicle group. The direct comparison model 
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showed that expression of three genes decreased (in panel) after combination 
therapy (above). The magnitude of expression differences is shown as the 
base average ratio of the gene expression level in the treated mouse ischemic 
hippocampus relative to that in the vehicle-treated ischemic hippocampus. 
Higher expression in the hippocampus is shown in red and lower expression 
in blue; the colour intensity is proportional to the magnitude of the 
expression difference as indicated by the colour bar at the bottom of the 
figure. d, Overlapping genes in all compound-treated scaling groups. e, 
Selected gene expression (Rgs6,regulator of G-protein signaling 6) was 
validated in real-time PCR. Kcnmb, large-conductance calcium-activated; 
Tcf, T cell factor;MMP, matrix metalloproteinase;Dgke, iacylglycerol kinase, 
epsilon; Camk, calcium/calmodulin-dependent proten kinase; Eef. 
elongation factor; Selenbp2, Mus musculus selenium binding protein 2; 
Calm, calmodulin; Cbx, chromobox homolog;Grb, growth factor receptor 
bound protein 
 
Figure 3  Molecular profiling shifts in combination therapy comparing to 
that of single compound. a, The numbers of altered genes in ischemic mouse 
hippocampus treated with compounds alone (JA, CA) or in combination 
(JA+CA) and the combination of JA+BA relative to treatment with JA or BA. 
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c, Numbers indicate different and overlapping genes in hippocampus treated 
with a single compound or with combined compounds. Visualizing gene 
expression of JA, CA and two-compound treatment, compare NI (b) and 
JA+BA with single compounds (d). Only the 374 cDNAs exhibiting > 
1.25-fold mean difference between compounds and vehicle are shown. e, 
The gene expression profiles of all groups contrast in nine pathways. The 
374 cDNAs predicted the outcome in all effective groups and contribute to 
many pathways, such as Wnt, p53, MAPK and GPCR (arbitrary fold 
criterion depicted for graphic representation only). Red denotes an increased 
mRNA level compared with the average of all animals. Green denotes a 
decreased mRNA level. f, Erk-MAPK networks display in different groups. 
Only the gene altered significantly in all groups and which of the Pearson 
coefficients > 0.5 were selected and linked with a line. White, plum and 
cardinal red circles represent altered genes whose ratios exceeded 1.5, 1.7 
and 2.0, respectively. Green circles represent genes changed significantly by 
the combination treatment but not by the single treatment; blue circles are 
the genes only changed significantly by the single treatment. 
 
Figure 4 GSI of compound-oriented profiles of gene expression and 
validation by an independent experiment. a, Our global similarity analysis 
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approach compared with the Euclidean distance and Pearson coefficient. b, 
GSI and percent of overlapping and non-overlapping genes in the two 
groups. c, Hierarchical clustering and PCA indicate the existence of three 
categories of compound-dependent gene expression profiles(d). e, PCA 
indicated similar results of clustering analysis for the PC1, PC2 and PC3 
maps; the sum accounted for 81.08% of the variance in the data and the 
individual contributions were 57.63%, 13.15% and 10.30%, respectively. 
 
Figure 5 Gene expression profiles predict pharmacological outcomes. IV 
was significantly lower after treatment with all compounds except CM. a, IV. 
F =16.23, ** P < 0.01 vs. vehicle; mean ± SD, ANOVA, n = 10).b, 
Behaviour score (F = 12.34, ** P < 0.01 vs. vehicle; mean ± SD, ANOVA, n 
= 10). JA+CA and NI produced the highest scores. c, Magnetic resonance 
imaging (MRI) results were consistent with the behaviour scores in the PIV 
but not CIV. This pharmacological effect confirmed the categories based on 
gene expression profiles of the ischemic mouse hippocampus *, #P < 0.05, 
**, ##P < 0.01 vs. vehicle. 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.1
68
8.
1 
: P
os
te
d 
15
 M
ar
 2
00
8
Methods Summary 
 
GSI Approach  
 
    The similarity between chips can be calculated by pairing comparing 
gene expression profile. For two gene microarray a  and b , containing n  
genes, the gene expression vector is tni xxxxx ],,,,,[ 21 ……=  and 
t
nj yyyyy ],,,,,[ 21 ……=  respectively. The similarity between them can be 
calculated by cosine coefficient 
yx
yxsimilarity
⋅
⋅
=                               (1) 
Gene microarray can simultaneously detect expression of thousands of 
genes. For two gene expression vector x  and y , the significant expression 
gene is xGene  and yGene  respectively. In addition, the total expression 
gene is the union of xGene  and yGene . The number of total expression gene 
is geneChangen _ . The number of discrepancy genes is diffn , which means there are 
diffn  genes significantly expressed in microarray a  instead of b  or in the 
inverse situation. We calculated the similarity between two microarray data 
as 
geneChangediffgenediffgenetotalchip nnSimSimSimilarity ___ /)1( ×−−=            (2) 
Here, genetotalSim _  and genediffSim _  is the similarity of original gene data and 
the discrepancy genes according to formula (1). diffn  In addition, geneChangen _  
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is the number of discrepancy gene and all changed genes, respectively. The 
second half part of formula (2) is modification to the similarity of all 
changed genes. 
      The similarity can be used to evaluate the consistency of data from 
different blocks in one chip. Because certain ratio value of one gene maybe 
losts in the practice. We proposed a wrong data coefficient to describe those 
situations. It is calculated by 
               nmcoefwrong /1_ −=                             (3) 
Here, m  is the number of absent data and n  is the number of all genes in 
one microarray. Moreover, the similarity between different blocks is 
calculated by 
  )/)1((_ ___ geneChangediffgenediffgenetotalblock nnSimSimcoefWrongSimilarity ×−−×=   (4) 
The similarity between samples from same group can be calculated in the 
same manner. In addition, it can be used to describe the magnitude of 
biological variation. Moreover, the similarity of microarray data from 
different groups can also be calculated according to formula (2) to observe 
whether they have similar gene expression profile. Here, we used GSI to 
represent Similaritychip only and data of Similarityblock were not shown. 
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